Surface Oncology Inc

NASDAQ:SURF   1:07:21 PM EDT
1.72
-0.03 (-1.71%)
Products

Surface Oncology Achieves $30 Mln Milestone With First Patient Dosed In Glaxosmithkline Phase 1 Study

Published: 03/31/2022 11:47 GMT
Surface Oncology Inc (SURF) - Surface Oncology Achieves $30 Million Milestone With First Patient Dosed in Glaxosmithkline Phase 1 Study.
Surface Oncology Inc - Will Receive a $30 Million Milestone Payment.
Surface Oncology - Eligible to Receive an Additional $700 Million in Potential Future Milestone Payments, As Well As Tiered Royalties on Global Net Sales.